Ischemia

REGENATIVE LABS AND DR. MICHAEL LAVOR ANNOUNCE CASE STUDY DEMONSTRATING NOVEL APPLICATION OF UMBILICAL CORD FLOWABLE TISSUE ALLOGRAFTS IN DECUBITUS ULCERS

Retrieved on: 
Monday, January 23, 2023
Silver sulfadiazine, Ischemia, Connective tissue, Physician, Standard of care, Pain, Medicine, Cancer staging, Granulation tissue, SDU, Patient, Research, Allotransplantation, Medical imaging, Veterinary medicine, Regenerative medicine, Jelly

PENSACOLA, Fla., Jan. 23, 2023 /PRNewswire/ -- A case study analysis of two patients has been presented by Regenative Labs (Regenative), a leading HCT/P manufacturer, in collaboration with Dr. Michael Lavor of Saguaro Surgical.

Key Points: 
  • PENSACOLA, Fla., Jan. 23, 2023 /PRNewswire/ -- A case study analysis of two patients has been presented by Regenative Labs (Regenative), a leading HCT/P manufacturer, in collaboration with Dr. Michael Lavor of Saguaro Surgical.
  • I believe this is an excellent step prior to surgery, and will save hundreds of thousands of dollars."
  • This case study demonstrates an application of Wharton's Jelly allografts in late-stage sacral decubitus ulcers (SDU), also known as pressure sores, with associated tunneling in combination with standard of care.
  • Both patients in the presented case study had SDU classified as Stage IV with tissue loss and bone or tendon involvement.

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

Retrieved on: 
Wednesday, February 1, 2023
United, BCDA, Heart, Ischemia, Quality of life, Myocardial infarction, AMI, Therapy, Helix, Physician, Patient, Union, Partnership, Organization, ATMP, Heart failure, Pharmaceutical industry, Medical device

The agreement relates to CellProthera’s use of BioCardia’s Helix™ transendocardial biotherapeutic delivery system for its ongoing Phase I/IIb EXCELLENT study of its lead product candidate ProtheraCytes™.

Key Points: 
  • The agreement relates to CellProthera’s use of BioCardia’s Helix™ transendocardial biotherapeutic delivery system for its ongoing Phase I/IIb EXCELLENT study of its lead product candidate ProtheraCytes™.
  • BioCardia’s Helix Biotherapeutic Delivery System is the leading percutaneous catheter delivery system for cardiovascular regenerative medicine.
  • It enables local delivery of cell and gene-based therapies to treat heart failure, myocardial infarction, ischemia, and cardiac conduction disorders.
  • However should it not, BioCardia would receive low single digit royalty on net sales of CellProthera’s transendocardially delivered ProtheraCytes for its contributions to CellProthera’s development efforts.

InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year Expenses

Retrieved on: 
Tuesday, January 24, 2023
Quality control, McGill University Health Centre, Ischemia, Cardiomyopathy, Bone marrow, CGMP, B cell, Commitment, HEM, Federal, Letter, Ischemic cardiomyopathy, Clinical trial, News, Pharmaceutical industry

The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.

Key Points: 
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “Hemostemix” in the search box.
  • The company is hiring an experienced stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists.
  • For more information, please visit the company’s website at www.hemostemix.com , contact Thomas Smeenk, President, CEO and Co-Founder at 905-580-4170 or by email at [email protected] .

InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01

Retrieved on: 
Monday, January 23, 2023
Disease, MUHC, Department of Mechanical Engineering, Imperial College London, Systematic review, McGill University, Principal, McGill University Health Centre, Beckman Research Institute, Ischemia, Cardiomyopathy, Blood, Bone marrow, B cell, Commitment, HEM, Research, Mechanical engineering, Myocardial infarction, Cardiology, Heart failure, Dream, Letter, Patient, Ischemic cardiomyopathy, Partnership, Clinical trial, Surgery, Research institute, Meta-analysis, Regeneration, Medicine, MI, Associate, Stanford University, McGill, Department of Medicine – University of Pamplona, News, Pharmaceutical industry

If these links are not enabled, please visit www.InvestmentPitch.com and enter “Hemostemix” in the search box.

Key Points: 
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “Hemostemix” in the search box.
  • In 2020, the MUHC Foundation launched its $200 million Dream Big Campaign to change the course of lives and medicine.
  • To reach that goal, Hemostemix and the MUHC Foundation are committed to working together with federal and provincial partners alongside donors to fund the phase II clinical trial at the McGill University Health Centre.
  • The MUHC Foundation is proud to help bring this ground-breaking clinical trial to the MUHC.

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, January 18, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Toxicity, ASCO, IA, Neoplasm, 2021 Essex County Council election, LAPC, PK, Pancreatic cancer, IV, MVT, SBRT, Amer, Ischemia, Cancer, III, IMRT, Medical imaging, Pharmaceutical industry, MD, Patient

The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (LAPC).

Key Points: 
  • The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (LAPC).
  • The substudy concludes that RenovoTAMP may increase local gemcitabine concentration, which may be beneficial in decreasing gemcitabine-related systemic side effects.
  • “Targeted local delivery of standard dose gemcitabine via the RenovoTAMP therapy platform may be associated with significantly less systemic drug exposure.
  • The poster presentations for the four RenovoRx abstracts to be presented at the ASCO GI Symposium will be available on RenovoRx’s website once available: https://renovorx.com/for-clinicians/ .

Athersys Provides MultiStem Clinical Update

Retrieved on: 
Monday, January 9, 2023
Stem Cells, Biotechnology, Manufacturing, Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Genetics, Science, Clinical Trials, Ischemia, Internet, EMA, McGovern Medical School, European Medicines Agency, University, Blood, Tissue, TPA, Mitsubishi, World Stroke Organization, Autoimmunity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Regenerative medicine, Nature Reviews Neurology, Safety, University of Texas Health Science Center at Houston, FDA, Trauma, Inflammation, 3D, Department of Defense Serum Repository, Partnership, Houston Methodist Hospital, Conference, Protein, Central nervous system, FAHA, Resuscitation, Mitsubishi UFJ Financial Group, Weill Cornell Medicine, Food, Patient, Children's Memorial Hermann Hospital, State, Memorial Hermann–Texas Medical Center, Stroke, Trauma Center, Trauma center, MTEC, Pharmaceutical industry, Vaccine, Neurology

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).
  • MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions.
  • MASTERS-2 is a company-sponsored Phase 3 randomized, double-blind, placebo-controlled trial evaluating MultiStem for the treatment of acute ischemic stroke.
  • Athersys’ enthusiasm about MultiStem for the treatment of ischemic stroke has been bolstered by results from completed clinical trials, and we look forward to providing updates on MASTERS-2 after we engage with regulatory authorities during the first quarter of 2023,” stated Dan Camardo, Chief Executive Officer of Athersys.

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Retrieved on: 
Thursday, December 15, 2022
Psilocybin, Acquisition, Reperfusion injury, NI, Canadian Securities Exchange, Revive, Disorder, Liver disease, Inflammation, Ischemia, Therapy, FDA, Offering, Person, Organ transplantation, Regulation, Sale, News, Risk, Indian stock exchange, Legislation, Part, CSE, Drug development, Orphan drug, SEDAR, Autoimmune hepatitis, Infection, Research, RVV, COVID-19, Unit, Security (finance), CBD

There is an amended and restated offering document dated December 14, 2022 (the “Offering Document”) related to the Offering that can be accessed under the Company’s profile at www.sedar.com and on the Company’s website at https://revivethera.com .

Key Points: 
  • There is an amended and restated offering document dated December 14, 2022 (the “Offering Document”) related to the Offering that can be accessed under the Company’s profile at www.sedar.com and on the Company’s website at https://revivethera.com .
  • As disclosed in the Offering Document, the company intends to use the net proceeds for general working capital purposes and clinical development.
  • Due to the Offering being expanded to Quebec investors, the Offering is now expected to close in one or more tranches with the first tranche anticipated to close on or before December 30, 2022.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Retrieved on: 
Thursday, December 15, 2022
Complex regional pain syndrome, Status epilepticus, Liver, Neurological disorder, Emergency, Life expectancy, Diagnosis, Disorder, Quality of life, Mortality, Reperfusion, Incidence, Ischemia, Kidney, Food, Marketing, FDA, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Organ transplantation, Neuromuscular disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seizure, Amyotrophic lateral sclerosis, Heart, Ischemic preconditioning, CSE, IL-6, Disease, Orphan drug, Orphan Drug Act of 1983, Transplant, Lung, OTCQB, IRI, Red blood cell, Injury, Rett syndrome, Patient, Mental health, Pharmaceutical industry, Dentistry, Vaccine, Ketamine

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.

Key Points: 
  • TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.
  • Fabio Chianelli, CEO of PharmaTher, commented: “This is our fourth orphan drug designation granted by the FDA for ketamine.
  • Organ Procurement and Transplantation Network, there were 41,355 solid organ transplantations in 2021, and thus far in 2022, there has been 39,241 solid organ transplantation with approximately 105,000 patients waiting for solid organ transplants in the United States.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.

American Endovascular & Amputation Prevention LLC Transitions to eClinicalWorks to Eliminate Administrative Burden

Retrieved on: 
Wednesday, December 14, 2022
Technology, Health Technology, Software, Practice Management, Other Health, Internet, Health, General Health, Data Management, ENDO, Cloud, Moyamoya disease, Physician, EHR, Electronic health record, ESRD, PAE, PRISMA, Patient, 3D ultrasound, Prostatic artery embolization, Automation, Amputation, Multimedia, Uterine artery embolization, PAD, Ischemia, Practice management software, CLI, Database, Venous insufficiency, Robotic process automation, Medical imaging, Medicine

eClinicalWorks , the largest ambulatory cloud EHR, today announced that American Endovascular & Amputation Prevention LLC transitioned to eClinicalWorks multi-dimensional EHR solution.

Key Points: 
  • eClinicalWorks , the largest ambulatory cloud EHR, today announced that American Endovascular & Amputation Prevention LLC transitioned to eClinicalWorks multi-dimensional EHR solution.
  • This added administrative work for physicians and slowed down our practice workflows, said Deborah Helmer, COO of American Endovascular.
  • American Endovascular affiliated physicians are at the forefront of the battle to prolong life by preventing amputations.
  • The American Endovascular affiliated physicians are proud to offer high-quality, compassionate endovascular care for patients throughout New Jersey, New York, and Ohio.

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Retrieved on: 
Wednesday, November 30, 2022
Psilocybin, COVID-19, Autoimmune hepatitis, Regulation, RVV, Inflammation, Revive, Disorder, Part, Liver disease, Canadian Securities Exchange, Acquisition, Ischemia, NI, Legislation, Organ transplantation, Unit, Orphan drug, Drug development, SEDAR, News, Infection, Sale, Indian stock exchange, Research, Therapy, Risk, Offering, Person, CSE, FDA, Reperfusion injury, Pharmaceutical industry, Security (finance), CBD

There is an offering document (the Offering Document) related to the Offering that can be accessed under the Companys profile at www.sedar.com and on the Companys website at https://revivethera.com .

Key Points: 
  • There is an offering document (the Offering Document) related to the Offering that can be accessed under the Companys profile at www.sedar.com and on the Companys website at https://revivethera.com .
  • As disclosed in the Offering Document, the company intends to use the net proceeds for general working capital purposes and clinical development.
  • The Offering is anticipated to close on or about December 14, 2022, or such later date as the Company may determine.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.